| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
|
Medicine details |
|
| Medicine name | brentuximab vedotin (Adcetris®) |
| Formulation | powder for solution for infusion |
| Reference number | 1693 |
| Indication | Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least 1 prior systemic therapy |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/01/2018 |
| NICE guidance | TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |